Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Lu Hongbo | Director | Dec 23 | Buy | 7.25 | 758,620 | 5,499,995 | 4,340,212 | Dec 23 05:44 PM | | Vivo Opportunity, LLC | 10% Owner | Dec 23 | Buy | 7.25 | 758,620 | 5,499,995 | 4,340,212 | Dec 23 05:48 PM | | ORBIMED ADVISORS LLC | Director | Dec 23 | Buy | 7.25 | 137,931 | 1,000,000 | 4,882,854 | Dec 28 05:57 PM | | GORDON CARL L | Director | Dec 23 | Buy | 7.25 | 137,931 | 1,000,000 | 4,882,854 | Dec 28 05:46 PM | | LAV Biosciences Fund V, L.P. | 10% Owner | Nov 23 | Sale | 5.50 | 1,500,000 | 8,250,000 | 405,583 | Nov 28 04:56 PM | | Lu Hongbo | Director | Sep 07 | Buy | 3.60 | 600,000 | 2,160,000 | 3,581,592 | Sep 08 08:00 PM | | Vivo Opportunity, LLC | 10% Owner | Sep 07 | Buy | 3.60 | 600,000 | 2,160,000 | 3,581,592 | Sep 08 08:00 PM | | ORBIMED ADVISORS LLC | Director | Aug 16 | Buy | 2.42 | 3,690,000 | 8,929,800 | 4,744,923 | Aug 18 05:00 PM | | GORDON CARL L | Director | Aug 16 | Buy | 2.42 | 3,690,000 | 8,929,800 | 4,744,923 | Aug 18 04:50 PM | | Vivo Opportunity, LLC | 10% Owner | Aug 16 | Buy | 2.42 | 1,500,000 | 3,630,000 | 2,981,592 | Aug 16 08:44 PM | | Lu Hongbo | Director | Aug 16 | Buy | 2.42 | 1,500,000 | 3,630,000 | 2,981,592 | Aug 16 08:30 PM | | Lu Hongbo | Director | Aug 15 | Buy | 2.99 | 1,218 | 3,642 | 1,481,592 | Aug 16 08:30 PM | | Vivo Opportunity, LLC | 10% Owner | Aug 15 | Buy | 2.99 | 1,218 | 3,642 | 1,481,592 | Aug 16 08:44 PM | | Vivo Opportunity, LLC | 10% Owner | Aug 12 | Buy | 2.98 | 1,123,021 | 3,346,603 | 1,480,374 | Aug 16 08:44 PM | | Lu Hongbo | Director | Aug 12 | Buy | 2.98 | 1,123,021 | 3,346,603 | 1,480,374 | Aug 16 08:30 PM |
|
